Infliximab and Abatacept Interaction
Drug interaction information between Infliximab and Abatacept.
Infliximab and Abatacept have a documented moderate interaction in FDA labeling.
FDA drug labeling documents a moderate-severity interaction between Infliximab and Abatacept. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.
How They Interact
Both drugs weaken the immune system, which makes it much harder for the body to fight off serious infections. Using them together does not provide any extra health benefits.
FDA Label Information
An increased risk of serious infections was seen in clinical studies of other TNF blockers used in combination with anakinra or abatacept, with no added clinical benefit. Because of the nature of the adverse reactions seen with these combinations with TNF blocker therapy, similar toxicities may also result from the combination of anakinra or abatacept with other TNF blockers. Therefore, the combination of INFLECTRA and anakinra or abatacept is not recommended [see Warnings and Precautions (5.10) ] .
Infliximab Also Interacts With
- Folic Acid minor
- Warfarin minor
- Methotrexate minor
- Ciprofloxacin minor
- Cyclosporine minor
Abatacept Also Interacts With
- Adalimumab moderate
- Certolizumab moderate
- Etanercept moderate
- Golimumab moderate
Frequently Asked Questions
What SPL severity band is on file for Infliximab + Abatacept?
Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.
Which drug in this pair has the larger labeled-interaction portfolio?
Infliximab has 8 labeled pairs on file vs Abatacept's 5. In the moderate band specifically: Infliximab has 1; Abatacept has 5 (also Adalimumab, Certolizumab, Etanercept, Golimumab).
What mechanism field is on file for Infliximab and Abatacept?
Both drugs weaken the immune system, which makes it much harder for the body to fight off serious infections. Using them together does not provide any extra health benefits.
Infliximab's labeled portfolio outnumbers Abatacept
SPL source-record counts only. This page's band is moderate · classes on file: Infliximab (TNF-Alpha Inhibitor (Biologic)); Abatacept (T-Cell Co-Stimulation Modulator).
0 major · 1 moderate · 7 minor · 8 total
Infliximab has no other moderate-band peer in this dataset besides Abatacept.
0 major · 5 moderate · 0 minor · 5 total
- Other moderate peers for Abatacept
- Adalimumab
- Certolizumab
- Etanercept
- Golimumab
Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.
Read our methodology - how this data is sourced, computed, and verified.